Promotes and finances translational research projects
in the EU

  • Financial Contribution:

    11 mil. €

    UE contribution

  • Duration:

    5 years

    Start: 6 April 2021


A consolidated and highly experienced network of 31 regional and national, public and private funding organisations from 20 European and non-European countries joined the EU-funded TRANSCAN-3 programme (, which aims at supporting high-impact translational cancer research. The overall objectives of TRANSCAN-3 are:

  • To strategically pool regional and national public and private resources dedicated to cancer research;
  • To align national and regional public and private cancer research programmes; and,
  • To strengthen, widen and make sustainable the existing network of funders.

The main instrument to achieve these objectives is the launch of joint transnational calls (JTCs) on translational cancer research with the purpose to fund excellent research projects, to address research on the most relevant topics, and to boost transnational scientific collaborations. The first EU co-funded JTC was launched in 2021 on the topic “Next-generation Cancer Immunotherapy targeting the tumour microenvironment” and is currently at the proposal evaluation stage. The TRANSCAN-3 programme also foresees the launch of three additional joint calls, without EU co-funding, on the second, third and fourth year of the project.

ACC is a member of the TRANSCAN-3 network and participates in each JTC with an earmarked budget of 300,000 euros to finance a maximum of two projects. ACC is also in charge of implementation the second JTC (JTC 2022).

JTC 2022

The JTC 2022 is focussed on “Novel translational approaches to tackle the challenges of hard-to-treat cancers from early diagnosis to therapy”. The Call Text and further details are available at Only researchers affiliated to comprehensive cancer patient care and research (IRCCS) that are members of ACC are eligible for funding from ACC. ACC will grant an eligibility clearance to applicants prior to submission of pre-proposals. To this end, applicants must complete and return a pre-eligibility check form linked at the bottom of this page to at least 10 working days before preproposal submission deadline. All applicants will receive a written notification that clarifies their eligibility status.

In continuity with the previous TRANSCAN-2, the ERA-NET TRANSCAN-3 programme aims to coordinate national and regional funding programmes for translational cancer research.

The challenge is to promote a transnational collaborative approach avoiding overlapping efforts and ensure more efficient use of available resources, producing higher quality and impactful results and sharing data and infrastructure. The Ministry of Health coordinates the project. 👇

Download the form

Project coordinator

Giandomenico Russo - Giulia Piaggio

The scientific coordination is by Dr. Giandomenico Russo, of the Istituto Dermopatico dell'Immacolata in Rome and Dr. Giulia Piaggio of IRE in Rome